WO1998035985B1 - Protein markers for lung cancer and use thereof - Google Patents
Protein markers for lung cancer and use thereofInfo
- Publication number
- WO1998035985B1 WO1998035985B1 PCT/IB1998/000361 IB9800361W WO9835985B1 WO 1998035985 B1 WO1998035985 B1 WO 1998035985B1 IB 9800361 W IB9800361 W IB 9800361W WO 9835985 B1 WO9835985 B1 WO 9835985B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- animal
- human
- spot
- lung cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Abstract
Computerized analysis of 2-D gels, both carrier ampholyte (CA) and immobilized pH gradient (IPG) based, of the proteins in tissue from lung tumors, reveals proteins which are different types of tumors and in control tissues.
Claims
AMENDED CLAIMS
[received by the International Bureau on 25 September 1998 (25.09.98); new claims 19-24 added, remaining claims unchanged (1 page)]
18. A method of treating a tumor in an animal or human in need thereof
comprising: a) exposing immunocompetent cells from the animal or human to at least
one protein selected from the group consisting of Spot 14, 15, 16, 17, 21 , 22, 27,
29, 31 , 33, 40, 42, 43, 47, 50, 53, 57, 58, 59, 61 , 62, 66, 67, 68, 73, 74, 79, 80,
81 , 83, 84, 86, 90, 92, 94, 95, 96, 97, 98, 100, 101 , 102, 105, 106, 107, and 109;
and b) injecting said immunocompetent cells into the animal or human to treat
a tumor.
19. A method for diagnosing lung cancer in an animal or human,
comprising detecting at least one protein which is overexpressed in lung tumors
in a sample from the animal or human, and correlating the detection of the
protein with the presence of lung tumor.
20. The method of claim 19, wherein the sample is serum.
21. The method of claim 19, wherein the at least one protein is spot 107
or spot 109.
22. A method for diagnosing lung cancer in an animal or human,
comprising detecting the overexpression of at least one protein which is
overexpressed in lung tumors in a sample from the animal or human, and
correlating the overexpression of the protein with the presence of lung tumor.
23. The method of claim 22, wherein the sample is serum.
24. The method of claim 22, wherein the at least one protein is spot 107
or spot 109.
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98905576A EP0961780B1 (en) | 1997-02-12 | 1998-02-12 | Protein markers for lung cancer and use thereof |
| DE69837529T DE69837529T2 (en) | 1997-02-12 | 1998-02-12 | PROTEIN MARKERS FOR LUNG CANCER AND ITS USE |
| AU61112/98A AU6111298A (en) | 1997-02-12 | 1998-02-12 | Protein markers for lung cancer and use thereof |
| JP53551498A JP4367866B2 (en) | 1997-02-12 | 1998-02-12 | Protein markers for lung cancer and uses thereof |
| CA2280930A CA2280930C (en) | 1997-02-12 | 1998-02-12 | Protein markers for lung cancer and use thereof |
| NZ337750A NZ337750A (en) | 1997-02-12 | 1998-02-12 | Protein markers for lung cancer and use thereof |
| DK98905576T DK0961780T3 (en) | 1997-02-12 | 1998-02-12 | Protein markers for lung cancer and its use |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3881997P | 1997-02-12 | 1997-02-12 | |
| US60/038,819 | 1997-02-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1998035985A1 WO1998035985A1 (en) | 1998-08-20 |
| WO1998035985B1 true WO1998035985B1 (en) | 1998-11-12 |
Family
ID=21902087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB1998/000361 Ceased WO1998035985A1 (en) | 1997-02-12 | 1998-02-12 | Protein markers for lung cancer and use thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20020192228A1 (en) |
| EP (1) | EP0961780B1 (en) |
| JP (1) | JP4367866B2 (en) |
| AT (1) | ATE359515T1 (en) |
| AU (1) | AU6111298A (en) |
| CA (1) | CA2280930C (en) |
| DE (1) | DE69837529T2 (en) |
| DK (1) | DK0961780T3 (en) |
| ES (1) | ES2284200T3 (en) |
| NZ (1) | NZ337750A (en) |
| WO (1) | WO1998035985A1 (en) |
Families Citing this family (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6960570B2 (en) | 1998-03-18 | 2005-11-01 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US6660838B1 (en) | 1998-03-18 | 2003-12-09 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
| US7258860B2 (en) | 1998-03-18 | 2007-08-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US7049063B2 (en) | 1998-03-18 | 2006-05-23 | Corixa Corporation | Methods for diagnosis of lung cancer |
| US6531315B1 (en) | 1998-03-18 | 2003-03-11 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US6518256B1 (en) | 1998-03-18 | 2003-02-11 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
| US6821518B1 (en) | 1998-03-18 | 2004-11-23 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
| US6426072B1 (en) | 2000-08-02 | 2002-07-30 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US6312695B1 (en) | 1998-03-18 | 2001-11-06 | Corixa Corporation | Compounds and methods for therapy of lung cancer |
| US6737514B1 (en) | 1998-12-22 | 2004-05-18 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US7579160B2 (en) | 1998-03-18 | 2009-08-25 | Corixa Corporation | Methods for the detection of cervical cancer |
| US6706262B1 (en) | 1998-03-18 | 2004-03-16 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
| US6696247B2 (en) | 1998-03-18 | 2004-02-24 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
| US6482597B1 (en) | 1999-12-17 | 2002-11-19 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
| EP1125134B1 (en) * | 1998-11-05 | 2009-11-04 | The Regents Of The University Of Michigan | S100 proteins and autoantibodies as serum markers for cancer |
| AU2004201392B2 (en) * | 1998-11-05 | 2007-06-14 | The Regents Of The University Of Michigan | S100 proteins and autoantibodies as serum markers for cancer |
| HUP0200760A2 (en) * | 1999-04-02 | 2002-06-29 | Corixa Corp | Compounds and methods for therapy and diagnosis of lung cancer |
| CA2394914A1 (en) | 1999-11-22 | 2001-05-31 | Susana Salceda | A novel method of diagnosing, monitoring, staging, imaging and treating cancer |
| CA2427643C (en) | 2000-11-02 | 2014-04-15 | Molecular Discoveries, L.L.C. | Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc) |
| US20030199685A1 (en) * | 2001-03-12 | 2003-10-23 | Monogen, Inc. | Cell-based detection and differentiation of disease states |
| AU2003236762A1 (en) * | 2002-07-05 | 2004-01-23 | Universite Laval | Chemotactic factor inhibitor for modulating inflammatory reactions |
| AU2002951153A0 (en) * | 2002-09-02 | 2002-09-19 | Proteome Systems Intellectual Property Pty Ltd | An electrophoresis gel having improved swelling properties |
| WO2005110456A2 (en) * | 2004-05-11 | 2005-11-24 | Abgenomics Corporation | T-cell death-inducing epitopes |
| US20070231317A1 (en) * | 2004-07-13 | 2007-10-04 | Universite Laval | S100 Protein Inhibitors for Treating Leukemia |
| US7659087B2 (en) * | 2004-07-23 | 2010-02-09 | Aspenbio Pharma, Inc. | Methods and devices for diagnosis of appendicitis |
| CN101124336A (en) | 2004-07-23 | 2008-02-13 | 阿斯彭生物制药有限公司 | Method and apparatus for diagnosing appendicitis |
| HRP20120154T1 (en) | 2005-05-18 | 2012-03-31 | Array Biopharma | HETEROCYCLIC MEK INHIBITORS AND METHODS OF THEIR USE |
| KR100732298B1 (en) * | 2005-11-24 | 2007-06-25 | 이화여자대학교 산학협력단 | Cancer metastasis diagnostic composition using ubiquitin C-terminal hydrolyzate-L1 |
| TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
| CL2007002225A1 (en) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A |
| AU2007287430B2 (en) | 2006-08-23 | 2011-07-21 | Kudos Pharmaceuticals Limited | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors |
| AR065784A1 (en) | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | DERIVATIVES OF 8-OXO ADENINE, DRUGS THAT CONTAIN THEM AND USES AS THERAPEUTIC AGENTS FOR ALLERGIC, ANTIVIRAL OR ANTIBACTERIAL DISEASES. |
| EP2138497A4 (en) | 2007-03-20 | 2012-01-04 | Dainippon Sumitomo Pharma Co | Novel adenine compound |
| ES2490165T3 (en) * | 2007-09-11 | 2014-09-03 | Cancer Prevention And Cure, Ltd. | Method that facilitates the diagnosis and treatment of asthma and lung cancer |
| WO2009047563A1 (en) | 2007-10-11 | 2009-04-16 | Astrazeneca Ab | Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors |
| JP5421925B2 (en) | 2007-12-19 | 2014-02-19 | ジェネンテック， インコーポレイテッド | 5-Anilinoimidazopyridine and method of use |
| BRPI0819505A2 (en) | 2007-12-21 | 2017-04-04 | Genentech Inc | "compound, pharmaceutical composition, method for inhibiting abnormal cell growth and method for treating an inflammatory disease" |
| WO2010032060A1 (en) | 2008-09-19 | 2010-03-25 | Medimmune Llc | Antibodies directed to dll4 and uses thereof |
| TW201028410A (en) | 2008-12-22 | 2010-08-01 | Astrazeneca Ab | Chemical compounds 610 |
| US20120114667A1 (en) | 2008-12-23 | 2012-05-10 | Medimmune Limited | TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF |
| CN105175434A (en) | 2009-02-05 | 2015-12-23 | 伊缪诺金公司 | Novel benzodiazepine derivatives |
| ES2703714T3 (en) | 2009-03-12 | 2019-03-12 | Cancer Prevention & Cure Ltd | Methods of identification, evaluation, prevention and therapy of pulmonary diseases and kits thereof, including the identification, evaluation, prevention and therapy of diseases on the basis of gender |
| ES2529205T3 (en) | 2009-03-13 | 2015-02-17 | Cellzome Limited | Pyrimidine derivatives as mTOR inhibitors |
| WO2010118986A1 (en) | 2009-04-14 | 2010-10-21 | Cellzome Limited | Fluoro substituted pyrimidine compounds as jak3 inhibitors |
| US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
| US20120172385A1 (en) | 2009-09-11 | 2012-07-05 | Richard John Harrison | Ortho substituted pyrimidine compounds as jak inhibitors |
| CN102666545B (en) | 2009-10-20 | 2016-04-06 | 塞尔卓姆有限公司 | As the heterocycle Pyrazolopyrimidine analogs of JAK inhibitor |
| KR101740171B1 (en) | 2009-11-24 | 2017-05-25 | 메디뮨 리미티드 | Targeted binding agents against b7-h1 |
| WO2011068233A1 (en) | 2009-12-03 | 2011-06-09 | Dainippon Sumitomo Pharma Co., Ltd. | Imidazoquinolines which act via toll - like receptors (tlr) |
| US20120315641A1 (en) * | 2010-01-08 | 2012-12-13 | The Regents Of The University Of California | Protein Markers for Lung Cancer Detection and Methods of Using Thereof |
| KR20130009760A (en) | 2010-02-10 | 2013-01-23 | 이뮤노젠 아이엔씨 | Cd20 antibodies and uses thereof |
| WO2011107585A1 (en) | 2010-03-04 | 2011-09-09 | Cellzome Limited | Morpholino substituted urea derivatives as mtor inhibitors |
| MX2012012328A (en) | 2010-04-30 | 2013-05-06 | Cellzome Ltd | Pyrazole compounds as jak inhibitors. |
| SA111320519B1 (en) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | Pyrimidinyl compounds for use as ATR inhibitors |
| WO2012000970A1 (en) | 2010-07-01 | 2012-01-05 | Cellzome Limited | Triazolopyridines as tyk2 inhibitors |
| US9040545B2 (en) | 2010-08-20 | 2015-05-26 | Cellzome Limited | Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors |
| CN103298794A (en) | 2010-11-09 | 2013-09-11 | 塞尔卓姆有限公司 | Pyridine compounds and aza analogues thereof as TYK2 inhibitors |
| BR112013020540B1 (en) | 2011-02-15 | 2020-12-29 | Immunogen, Inc | methods for preparing conjugates comprising cell-binding agent conjugated to cytotoxic compound with linker group |
| CA2827172C (en) | 2011-02-17 | 2019-02-26 | Cancer Therapeutics Crc Pty Limited | Selective fak inhibitors |
| WO2012110773A1 (en) | 2011-02-17 | 2012-08-23 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
| WO2012136622A1 (en) | 2011-04-04 | 2012-10-11 | Cellzome Limited | Dihydropyrrolo pyrimidine derivatives as mtor inhibitors |
| WO2012143320A1 (en) | 2011-04-18 | 2012-10-26 | Cellzome Limited | (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors |
| WO2013014162A1 (en) | 2011-07-28 | 2013-01-31 | Cellzome Limited | Heterocyclyl pyrimidine analogues as jak inhibitors |
| WO2013017479A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| AU2012311504B2 (en) | 2011-09-20 | 2016-03-24 | Cellzome Limited | Pyrazolo[4,3-C]pyridine derivatives as kinase inhibitors |
| AU2012311458B2 (en) | 2011-09-21 | 2016-02-04 | Cellzome Limited | Morpholino substituted urea or carbamate derivatives as mTOR inhibitors |
| EP2763985B1 (en) | 2011-10-07 | 2016-06-22 | Cellzome Limited | {(4-(4-morpholino-dihydrothieno[3,4-d]pyrimidin-2-yl)aryl}urea or carbamate derivatives as mtor inhibitors |
| US20130178520A1 (en) | 2011-12-23 | 2013-07-11 | Duke University | Methods of treatment using arylcyclopropylamine compounds |
| BR112014015723A8 (en) | 2011-12-23 | 2017-07-04 | Cellzome Ltd | pyrimidine-2,4-diamine derivatives as kinase inhibitors |
| KR102172897B1 (en) | 2012-06-08 | 2020-11-02 | 서트로 바이오파마, 인크. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| DK2863955T3 (en) | 2012-06-26 | 2017-01-23 | Sutro Biopharma Inc | MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF |
| AU2013302320A1 (en) | 2012-08-17 | 2015-02-26 | Cancer Therapeutics Crc Pty Limited | VEGFR3 inhibitors |
| HK1211208A1 (en) | 2012-08-22 | 2016-05-20 | Immunogen, Inc. | Cytotoxic benzodiazepine derivative |
| JP6826367B2 (en) | 2012-08-31 | 2021-02-03 | ストロ バイオファーマ インコーポレーテッド | Modified amino acids containing azide groups |
| WO2014041349A1 (en) | 2012-09-12 | 2014-03-20 | Cancer Therapeutics Crc Pty Ltd | Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors |
| WO2014045101A1 (en) | 2012-09-21 | 2014-03-27 | Cellzome Gmbh | Tetrazolo quinoxaline derivatives as tankyrase inhibitors |
| JP6423804B2 (en) | 2013-02-28 | 2018-11-14 | イミュノジェン・インコーポレーテッド | Complex containing cell binding agent and cytotoxic agent |
| WO2014134483A2 (en) | 2013-02-28 | 2014-09-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| AR095443A1 (en) | 2013-03-15 | 2015-10-14 | Fundación Centro Nac De Investig Oncológicas Carlos Iii | HEREROCICLES CONDENSED WITH ACTION ON ATR |
| WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| US9764039B2 (en) | 2013-07-10 | 2017-09-19 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| US9840493B2 (en) | 2013-10-11 | 2017-12-12 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
| GB201510019D0 (en) | 2015-06-09 | 2015-07-22 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| SG11201806419RA (en) | 2016-01-27 | 2018-08-30 | Sutro Biopharma Inc | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates |
| CN107459519A (en) | 2016-06-06 | 2017-12-12 | 上海艾力斯医药科技有限公司 | Annelated pyrimidines piperidines ring derivatives and its preparation method and application |
| AU2017321973B2 (en) | 2016-09-02 | 2024-09-05 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating B cell disorders |
| US10786502B2 (en) | 2016-12-05 | 2020-09-29 | Apros Therapeutics, Inc. | Substituted pyrimidines containing acidic groups as TLR7 modulators |
| BR112019011284A2 (en) | 2016-12-05 | 2019-10-22 | Apros Therapeutics Inc | compound, pharmaceutical composition, methods of treating a condition, hbv and cancer, and, use of a compound. |
| CA3058481A1 (en) | 2017-04-04 | 2018-10-11 | Lung Cancer Proteomics, Llc | Plasma based protein profiling for early stage lung cancer prognosis |
| WO2019023316A1 (en) | 2017-07-26 | 2019-01-31 | Sutro Biopharma, Inc. | Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma |
| US10596270B2 (en) | 2017-09-18 | 2020-03-24 | Sutro Biopharma, Inc. | Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates |
| NL2019801B1 (en) | 2017-10-25 | 2019-05-02 | Univ Leiden | Delivery vectors |
| EP3802519A1 (en) | 2018-06-04 | 2021-04-14 | Apros Therapeutics, Inc. | Pyrimidine compounds containing acidic groups useful to treat diseases connected to the modulation of tlr7 |
| GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
| GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
| EP3852811A1 (en) | 2018-09-17 | 2021-07-28 | Sutro Biopharma, Inc. | Combination therapies with anti-folate receptor antibody conjugates |
| CA3130727A1 (en) | 2019-03-28 | 2020-10-01 | Amplia Therapeutics Limited | A salt and crystal form of a fak inhibitor |
| EP3962951A1 (en) | 2019-05-03 | 2022-03-09 | Sutro Biopharma, Inc. | Anti-bcma antibody conjugates |
| CA3152674A1 (en) | 2019-08-31 | 2021-03-04 | Etern Biopharma (Shanghai) Co., Ltd. | Pyrazole derivatives for fgfr inhibitor and preparation method thereof |
| US20230095053A1 (en) | 2020-03-03 | 2023-03-30 | Sutro Biopharma, Inc. | Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use |
| CN120076831A (en) | 2022-06-30 | 2025-05-30 | 苏特罗生物制药公司 | Anti-ROR 1 antibodies and antibody conjugates, compositions comprising anti-ROR 1 antibodies or antibody conjugates, and methods of making and using anti-ROR 1 antibodies and antibody conjugates |
| WO2025081117A2 (en) | 2023-10-13 | 2025-04-17 | Sutro Biopharma, Inc. | Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK276185D0 (en) * | 1984-11-09 | 1985-06-19 | Novo Industri As | MONOCLONAL ANTIBODIES, METHOD OF PREPARING THESE AND THEIR DIAGNOSTIC USES |
| US5019497A (en) * | 1984-11-09 | 1991-05-28 | Lennart Olsson | Human squamous lung carcinoma cell specific antigens and antibodies |
| US5171665A (en) * | 1989-04-17 | 1992-12-15 | Oncogen | Monoclonal antibody to novel antigen associated with human tumors |
| CH685959A5 (en) * | 1992-08-24 | 1995-11-15 | Biomedicals Ag | Diagnostic test kit for the determination of proteins. |
| EP0695760A1 (en) * | 1994-08-05 | 1996-02-07 | F. Hoffmann-La Roche Ag | Novel tumor marker for lung cancer |
| US6107103A (en) * | 1996-10-15 | 2000-08-22 | Procyon Bropharma Inc. | Assay for PSP94 protein |
-
1998
- 1998-02-12 WO PCT/IB1998/000361 patent/WO1998035985A1/en not_active Ceased
- 1998-02-12 EP EP98905576A patent/EP0961780B1/en not_active Expired - Lifetime
- 1998-02-12 JP JP53551498A patent/JP4367866B2/en not_active Expired - Fee Related
- 1998-02-12 ES ES98905576T patent/ES2284200T3/en not_active Expired - Lifetime
- 1998-02-12 US US09/022,527 patent/US20020192228A1/en not_active Abandoned
- 1998-02-12 NZ NZ337750A patent/NZ337750A/en not_active IP Right Cessation
- 1998-02-12 CA CA2280930A patent/CA2280930C/en not_active Expired - Fee Related
- 1998-02-12 AT AT98905576T patent/ATE359515T1/en active
- 1998-02-12 DK DK98905576T patent/DK0961780T3/en active
- 1998-02-12 DE DE69837529T patent/DE69837529T2/en not_active Expired - Lifetime
- 1998-02-12 AU AU61112/98A patent/AU6111298A/en not_active Abandoned
-
2003
- 2003-06-16 US US10/461,424 patent/US20050095249A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1998035985B1 (en) | Protein markers for lung cancer and use thereof | |
| DE69837529D1 (en) | PROTEIN MARKERS FOR LUNG CANCER AND ITS USE | |
| TAYLOR et al. | Immunofluorescent localization of vitamin D-dependent calcium-binding protein | |
| Ralston et al. | The product of the protooncogene c-src is modified during the cellular response to platelet-derived growth factor. | |
| DE69519796D1 (en) | PTPalpha determination in tumor diagnosis and prognosis | |
| CY1105446T1 (en) | DIAGNOSIS AND TREATMENT OF DISORDERS ASSOCIATED WITH AUR1 AND AUR2 | |
| EA200501772A1 (en) | METHODS OF MEASURING THE EXPRESSION OF GENES FROM FIXED AND PARULIN FABRIC SAMPLE | |
| AU2001253079A1 (en) | Methods, compositions and kits for the detection and monitoring of breast cancer | |
| EP0762885A4 (en) | GLOBAL MITOGENIC FACTORS, PREPARATION AND USE | |
| SE9500023L (en) | Ways to detect cancer | |
| Evans et al. | Gene-specific DNA repair in xeroderma pigmentosum complementation groups A, C, D, and F. Relation to cellular survival and clinical features. | |
| NZ332641A (en) | method of detecting a lysosomal storage disorder by assaying the level of an enzyme, protein or peptide associated with the disease | |
| BR9609026A (en) | Process composition for the treatment of cancer and detection for the production of cytokine by tumors to determine the efficacy of an autologous and diagnostic kit for detection for efficacy of autologous cellular compounds | |
| ATE466938T1 (en) | PROSTATE-SPECIFIC GENE PCGEM1 AND METHODS OF USE THEREOF FOR DETECTION, TREATMENT AND PREVENTION OF PROSTATE CANCER | |
| EA200000845A1 (en) | GENE ENCODING NEW CANCER MARKER | |
| CA2221495A1 (en) | Methods and uses for apoptin | |
| Holloway et al. | Localisation and expression of metallothionein immunoreactivity in the developing sheep brain | |
| ATE365326T1 (en) | METHOD FOR ANALYZING THE AMOUNT OF INTRA-ABDOMINAL FAT TISSUE | |
| John et al. | The detection and determination of L-tyrosine O-sulphate in rabbit and other mammalian urine | |
| Presta et al. | Human placental tissue stimulates bovine capillary endothelial cell growth, migration and protease production | |
| DE69735676D1 (en) | PROTEIN MARKERS FOR OASOPHAGUS CANCER | |
| DE69636041D1 (en) | IDENTIFICATION OF BREAST TUMORVIRUS-TYPE SEQUENCES IN BREAST CANCER IN HUMANS | |
| ATE304549T1 (en) | HUMAN NETRIN-1 | |
| Tofilon et al. | BCNU-induced sister chromatid exchanges are increased by X irradiation | |
| CA2415923A1 (en) | Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers |